Systemic Bioactivity of Inhaled Nebulized RNS60
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2015
At a glance
- Drugs RNS 60 (Primary)
- Indications Alzheimer's disease; Asthma; Multiple sclerosis; Myocardial infarction; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Revalesio
- 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Jul 2015 New trial record